SPINRAZA Drug Patent Profile

When do Spinraza patents expire, and when can generic versions of Spinraza launch?

Spinraza is a drug marketed by Biogen Idec and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seven patent family members in twenty-eight countries.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this compound. Additional details are available on the nusinersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Spinraza

Spinraza was eligible for patent challenges on December 23, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 11, 2027. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SPINRAZA

International Patents:	107
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	12
Patent Applications:	395
Drug Prices:	Drug price information for SPINRAZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SPINRAZA
What excipients (inactive ingredients) are in SPINRAZA?	SPINRAZA excipients list
DailyMed Link:	SPINRAZA at DailyMed

See drug prices for SPINRAZA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SPINRAZA

NDA:

209531

Dosage:

SOLUTION;INTRATHECAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SPINRAZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Biogen	Phase 4
NYU Langone Health	Early Phase 1
Winthrop University Hospital	Early Phase 1

See all SPINRAZA clinical trials

Pharmacology for SPINRAZA

Drug Class	Antisense Oligonucleotide Survival Motor Neuron-2-directed RNA Interaction
Physiological Effect	Increased Protein Synthesis

Paragraph IV (Patent) Challenges for SPINRAZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPINRAZA	Intrathecal Solution	nusinersen sodium	12 mg/5 mL	209531	1	2026-03-10

US Patents and Regulatory Information for SPINRAZA

SPINRAZA is protected by twenty US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-003	Mar 27, 2026		RX	Yes	Yes
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-003	Mar 27, 2026		RX	Yes	Yes
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-003	Mar 27, 2026		RX	Yes	Yes			Y	Y
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes

Expired US Patents for SPINRAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016

International Patents for SPINRAZA

See the table below for patents covering SPINRAZA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112017004056	composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
Chile	2017000594	Composiciones y métodos para detección de proteína smn en un sujeto y tratamiento de un sujeto
Chile	2019000447	Composiciones y métodos para detección de proteína smn en un sujeto y tratamiento de un sujeto. (divisional solicitud 201700594)
Colombia	2017002400	Composiciones y métodos para detección de proteína smn en un sujeto
World Intellectual Property Organization (WIPO)	2016040748

Supplementary Protection Certificates for SPINRAZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1910395	CA 2017 00054	Denmark		PRODUCT NAME: NUSINERSEN ELLER SALTE DERAF; REG. NO/DATE: EU/1/17/1188 20170601
1910395	300905	Netherlands		PRODUCT NAME: NUSINERSEN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1188 20170601
2548560	300902	Netherlands		PRODUCT NAME: NUSINERSEN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/17/1188 20170601
2548560	PA2017037	Lithuania		PRODUCT NAME: NUSINERSENAS ARBA JO DRUSKOS; REGISTRATION NO/DATE: EU/1/17/1188/001 20170530
2548560	CA 2017 00055	Denmark		PRODUCT NAME: NUSINERSEN ELLER SALTE DERAF; REG. NO/DATE: EU/1/17/1188 20170601

SPINRAZA market dynamics and financial trajectory (nusinersen): sales drivers, exclusivity, payer posture, and biosimilar/generic risk

Last updated: June 26, 2026

Executive summary: Spinraza (nusinersen, Biogen) has scaled to a mature, high-cost market driven by (1) expanded treated-patient pool and dosing retention, (2) multi-year payer contracting and managed-entry dynamics for a chronic intrathecal therapy, and (3) steady geography-by-geography reimbursement normalization. Financial trajectory hinges on balance between new patient starts and attrition, plus periodic list price and contracting outcomes in the US and EU. Patent and exclusivity headroom delays direct generic competition, but competitive pressure comes more from future technology displacement (next-gen SMA therapies), pricing pressure via payer step edits, and biosimilar-like “therapeutic alternatives” rather than immediate generic entry.

What to focus on: sales trend math (new starts vs continuation), US reimbursement and payer reimbursement caps, EU country-level HTA decisions, and timeline checkpoints for competitive launches and patent life.

---

How are Spinraza (nusinersen) sales growing and what drives market dynamics in SMA?

Featured snippet answer: Spinraza’s market dynamics track the number of ongoing treated patients and the cadence of new patient initiations under chronic dosing, with US and EU reimbursement continuity as the key short-term stabilizer.

What is the commercial model for nusinersen in SMA?

Spinraza is an intrathecal antisense oligonucleotide given on a loading regimen followed by maintenance dosing. Commercially, that structure creates:

• High persistence value: once patients start, many remain on therapy for years, supporting revenue durability.
• Start-driven inflection points: quarterly revenue growth is sensitive to how quickly new eligible patients are identified and onboarded.
• Payer risk controls: payers manage annual budget impact with prior authorization, step edits, and contracted discounts that can tighten during budget cycles.

Key market dynamics that move quarterly revenue

1. Eligibility expansion through early diagnosis
   • Broader newborn screening and earlier genetic confirmation increase the pool for early intervention, raising the number of patients likely to begin treatment.
2. Treatment initiation speed
   • Time from diagnosis to “first dose” varies by region, neuromuscular center capacity, and local reimbursement process.
3. Payer contracting and formulary placement
   • US and EU payer coverage determines whether new starts accelerate or slow.
4. Clinical adoption and switch behavior
   • For patients eligible for multiple SMA options, payer and physician preference can shift based on outcomes, safety profile, administration practicality, and price.

---

What is Spinraza’s financial trajectory (revenue trend, margins, and earnings sensitivity)?

Featured snippet answer: Spinraza revenue generally follows a growth-to-maturity pattern: expansion in treated patients early, then slower growth as the market saturates in treated cohorts and new start growth depends on diagnosis rates and payer access.

Biogen financial sensitivity and how investors model it

Spinraza sits inside Biogen’s neuromuscular franchise, so the market typically evaluates:

• Revenue per treated patient (list price net of rebates and contracts).
• New start volume and patient continuation.
• Regional mix (US vs Europe) because net pricing and HTA outcomes differ.
• Gross-to-net dynamics driven by contracting, rebates, and administration costs.

What tends to cause revenue upside/downside

• Upside: higher-than-expected eligible patient identification and coverage expansion; favorable payer renewals; stable continuation.
• Downside: tighter payer controls, adverse policy language in managed care contracts, delayed starts, and patient switching to other SMA mechanisms.

Note: This section is framed as a trajectory model rather than a quarter-by-quarter sales narrative because the prompt does not provide a specific reporting period or numeric revenue targets.

---

When does Spinraza lose exclusivity, and what does that mean for generic or biosimilar entry?

Featured snippet answer: Spinraza’s exclusivity is protected by a combination of composition-of-matter and formulation/use patent coverage that blocks generic substitution; direct generic entry is not an immediate threat on a typical exclusivity timeline.

Exclusivity vs patent expiration: what matters commercially

For a complex oligonucleotide therapy, practical entry depends on:

• Patent life for specific drug substance and delivery/formulation claims.
• Regulatory pathway feasibility (oligonucleotide generics are legally and scientifically constrained in many jurisdictions).
• Interchangeability and substitution norms.

How loss of exclusivity would translate to revenue risk

Even if core patents expire, revenue impact often shows up as:

• Delayed adoption of any “follow-on” product due to clinical confidence barriers.
• Tender-driven pricing and payer preference changes after sufficient evidence and contracting shifts.
• Patient retention risk if prescribers migrate to lower-cost alternatives.

---

What patents protect Spinraza (nusinersen), and how strong is the patent estate?

Featured snippet answer: Spinraza is protected by a layered patent estate covering antisense oligonucleotide sequences, chemical modifications, formulations, and therapeutic uses, creating multiple legal barriers to copying.

Patent-portfolio “barrier map” used in litigation and generic planning

• Drug substance composition claims: sequence, backbone chemistries, and modifications.
• Formulation and delivery claims: intrathecal suitability, stability, and manufacturing-related features where claimed.
• Method-of-use claims: dosing regimens and therapeutic indications in SMA.

How strength is typically measured by strategists

• Number of independent claims still enforceable across jurisdictions.
• Remaining term on key “core” patents versus later-expiring “surrounding” patents.
• Likelihood of claim construction disputes that could sustain injunction leverage.

Note: The prompt requests market dynamics and financial trajectory, but patent strength timelines are directly relevant to revenue risk modeling; this section keeps the analysis at an estate-structure level.

---

Is there any Paragraph IV challenge risk for Spinraza, and who would be the likely filers?

Featured snippet answer: Paragraph IV frameworks apply to small-molecule generics and many biologics pathways, but Spinraza’s oligonucleotide product profile makes “generic” challenges less straightforward than for conventional oral drugs.

What challengers would need to overcome

• Regulatory classification issues and pathway selection.
• Claim alignment for any purported “substantially similar” product.
• Patent coverage mapping around composition and method-of-use claims.

Market consequence if a challenge succeeds

• Immediate payer re-contracting and price compression in the affected jurisdictions.
• Switching risk increases only after a follow-on therapy establishes acceptable clinical outcomes and prescriber comfort.

---

What formulations or dosing regimens of Spinraza are protected, and how does that affect competition?

Featured snippet answer: Competition risk is reduced when patent coverage spans dosing regimens and intrathecal-specific formulation attributes that would be difficult to reproduce identically.

Dosing regimen protection: commercial relevance

• If maintenance and loading schedules are claimed, a competitor must navigate both sequence and regimen barriers.
• Even if sequence copying is partially possible, regimen differences can still trigger infringement if method-of-use claims are broad.

Intrathecal delivery: manufacturing and IP barriers

• Oligonucleotide stability, handling, and delivery systems are high-friction engineering problems.
• Patent claims tied to stability or administration-supporting components create “design-around” difficulty.

---

How do alternative SMA therapies affect Spinraza market share and pricing pressure?

Featured snippet answer: Spinraza’s competitive set increasingly includes other disease-modifying SMA modalities; the risk to Spinraza is displacement in newly diagnosed patients and payer substitution decisions, not rapid generic substitution.

Competitive displacement mechanism

• New starts shift first: once another therapy is preferred for eligible patients, Spinraza’s patient pool stops expanding at the rate it did earlier in market development.
• Treatment sequencing: clinicians may prefer newer options for certain genotypes or risk profiles.
• Payer economics: payers compare annual cost per quality-adjusted outcomes and negotiate discounts based on head-to-head effectiveness claims.

What pricing pressure looks like in practice

• Contracting shifts from list price anchoring to net price anchored around volume commitments and outcomes.
• HTA agencies can restrict reimbursement scope, forcing utilization management for specific subgroups.

---

What is the Orange Book status of Spinraza, and does it predict generic entry risk?

Featured snippet answer: For Spinraza (nusinersen), generic entry risk is better assessed through patent estate and oligonucleotide regulatory pathways rather than Orange Book listings alone.

Why Orange Book is not sufficient for oligonucleotide therapies

• Orange Book is oriented around approved drug products and patents eligible for listing; it may not capture the full scope of regulatory and IP barriers relevant to oligonucleotide “generic-like” follow-ons.
• Even with listed patents, the feasibility of substitution depends on pathway and claim coverage.

Note: This section is designed to capture the question intent. It does not provide listing-specific details because the prompt does not supply the Orange Book listing dataset.

---

How do payer policies and managed care dynamics shape Spinraza’s net price and continuation rates?

Featured snippet answer: Spinraza’s financial performance depends on net pricing outcomes and continuity of coverage for chronically treated patients; payer tightening tends to show up first as delayed starts.

US payer dynamics

Common levers:

• prior authorization criteria linked to diagnosis and gene testing documentation
• coverage for specific age bands or symptom statuses
• annual budget negotiation and rebate structures

EU payer dynamics

Common levers:

• HTA committee conditions tied to outcome evidence and patient selection
• re-evaluation cycles for cost-effectiveness
• national procurement contracts and payer-specific pricing

How this impacts financial trajectory

• Net price pressure: rebasing discounts during renewals can compress revenue even with stable treated volumes.
• Utilization management: reduces starts and can slow sales growth without immediately impacting continuity.

---

What litigation or settlements affect Spinraza’s competitive posture?

Featured snippet answer: Patent litigation, if active, affects the timing of any follow-on launch and can extend revenue protection through injunction leverage or settlement-based “carve-out” periods.

How to connect litigation to market outcomes

• A settlement can lock in launch timing or impose licensing fees, reducing probability of early pricing disruption.
• An adverse court outcome can accelerate entry, forcing payers to renegotiate.

Note: The prompt does not provide case identifiers or jurisdictions; this section remains at the litigation-to-revenue linkage level.

---

Which regions contribute most to Spinraza revenue, and where is the market most at risk?

Featured snippet answer: The highest risk regions for growth are those with strict HTA thresholds or frequent reimbursement reassessments; more stable revenue usually comes from markets with broad coverage and mature SMA care pathways.

Regional risk profiles used by market participants

• US: payer-by-payer variability; renewal cycles and pharmacy benefit dynamics can shift net pricing and start volumes.
• EU5 and select Asia markets: HTA and reimbursement scope are decisive, especially for early diagnosis cohorts.
• Rest of world: coverage expansion can lift treated population, but reimbursement volatility and access constraints can delay starts.

---

How many patients can be treated with Spinraza, and what does treated-patient growth imply for revenue?

Featured snippet answer: Revenue scales with the treated-patient base because chronic dosing drives multi-year persistence; patient growth must be estimated via eligible diagnosis pipelines, not just SMA incidence.

Revenue math framework

• Treated patient count at time t:
  • equals prior treated count minus attrition plus new starts.
• Revenue at time t:
  • approximates net price per dose schedule multiplied by dosing frequency across loading and maintenance phases.

What causes attrition risk

• disease progression and mortality dynamics
• discontinuation in rare safety events
• switching to alternatives

---

How does Spinraza compare with competing SMA drugs on commercial trajectory and payer economics?

Featured snippet answer: Compared with newer one-time or shorter-duration mechanisms, Spinraza’s commercial pattern is typically steadier but more exposed to long-term payer cost controls for chronic dosing.

Commercial comparison axes

• annual cost per patient
• administration burden and care pathway integration
• demonstrated durability of motor outcomes
• payer willingness to cover chronically

Likely displacement pattern

• New pediatric and early-diagnosis cohorts often become the primary battleground because treatment selection occurs earlier in disease and before long-established persistence patterns form.

---

Key Takeaways

• Spinraza’s market dynamics are dominated by treated-patient persistence and the throughput of new patient starts, moderated by payer coverage and managed-entry terms.
• Financial trajectory is sensitive to net pricing (rebates/discounts) and utilization management more than to short-term price changes.
• Patent and exclusivity protections delay direct generic substitution; competitive risk is primarily therapeutic displacement by other SMA mechanisms and payer-driven step edits.
• The revenue inflection points to monitor are reimbursement renewals, HTA re-scopes, and competitive shifts in newly diagnosed patient cohorts.

---

FAQs

1) What drives Spinraza revenue growth in the US quarter-to-quarter?
New patient start volume and maintenance dosing persistence, with net price shaped by contracting and rebate outcomes.

2) How do HTA decisions in Europe affect Spinraza access and sales?
Coverage scope restrictions and periodic re-evaluation cycles can delay starts or limit utilization to predefined patient subgroups.

3) Does the chronic intrathecal dosing schedule improve revenue stability?
Yes, it supports multi-year persistence, but it also increases payer budget scrutiny and the likelihood of utilization management over time.

4) What competitive event would most threaten Spinraza’s patient growth?
A shift in standard-of-care favoring alternative SMA therapies for newly diagnosed patients, combined with payer substitution and price contracting pressure.

5) How should investors assess the risk of follow-on entrants for Spinraza?
Model around patent estate strength, feasibility of regulated oligonucleotide follow-ons, and likely payer acceptance timelines rather than assuming rapid generic substitution.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. Biogen. (n.d.). Investor relations: Financial reports and annual/quarterly results. Biogen Inc.
3. EMA. (n.d.). European Public Assessment Reports (EPAR) database. European Medicines Agency.

DrugChatter Q&A for SPINRAZA

Spinraza patent expiration?